|
|
|
|
|
| Rodrigues,T.A.; Sampaio Junior,A.J.B.; Nunes,I.D.P.; Cartágenes,M.S.S.; Garcia,J.B.S.. |
| Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects of decreasing the risk of fractures and an indication of reducing the progression of osteoarthritis (OA). This study aimed to investigate the effects of SrRan as either a prophylactic or a treatment drug, using an OA rat model to assess pain behavior. A monoiodoacetate (MIA)-induced knee joint OA model in Wistar rats was used. Thirty Wistar rats (both sexes, 60 days old) were distributed in five groups of 6 rats each: the control group, that received no intervention; a prophylactic group, that received oral administration of 25 mg·kg-1·day-1 of SrRan for 28 days before induction of OA; a group treated with 25 mg·kg-1·day-1 of SrRan for 28 days after OA... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Osteoarthritis; Strontium ranelate; Pain; Treatment; Prophylaxis. |
| Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000900602 |
| |
|
|
| Geng,Tianxiang; Sun,Shouxuan; Yu,Haochen; Guo,Haohui; Zheng,Mengxue; Zhang,Shuai; Chen,Xi; Jin,Qunhua. |
| The imbalance between bone formation and osteolysis plays a key role in the pathogenesis of aseptic loosening. Strontium ranelate (SR) can promote bone formation and inhibit osteolysis. The aim of this study was to explore the role and mechanism of SR in aseptic loosening induced by wear particles. Twenty wild-type (WT) female C57BL/6j mice and 20 sclerostin-/- female C57BL/6j mice were used in this study. Mice were randomly divided into four groups: WT control group, WT SR group, knockout (KO) control group, and KO SR group. We found that SR enhanced the secretion of osteocalcin (0.72±0.007 in WT control group, 0.98±0.010 in WT SR group, P=0.000), Runx2 (0.34±0.005 in WT control group, 0.47±0.010 in WT SR group, P=0.000), β-catenin (1.04±0.05 in WT... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Strontium ranelate; Aseptic loosening; Sclerostin; Bone remodeling; Canonical Wnt pathway. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000900605 |
| |
|
| |
|
|
|
